PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Prescience International

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Personalized Medicine World Conference and Prescience International Announce Most Promising Company - Personalized Medicine World Conference (PMWC 2013) and Prescience International awarded Horizon Discovery Limited the Most Promising Company Award at PMWC 2013 held at the Computer History Museum in Silicon Valley January 28-29th
Personalized Medicine World Conference and Prescience International Announce Most Promising Company

 

NewswireToday - /newswire/ - San Francisco, CA, United States, 2013/02/11 - Personalized Medicine World Conference (PMWC 2013) and Prescience International awarded Horizon Discovery Limited the Most Promising Company Award at PMWC 2013 held at the Computer History Museum in Silicon Valley January 28-29th.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Chosen from an initial pool of 28 companies by a group of life science industry leaders and audience polling, Horizon Discovery was one of three finalists that included SV Bio and Telmedx.

UK-based Horizon Discovery has developed a translational genomics platform and drug discovery toolbox that enables the development of new therapies targeted at the genetic features that drive an individual's cancer. The award was accepted by Dr. Darrin Disley, CEO of Horizon, and Dr. Chris Torrance, CSO of Horizon.

Horizon's CEO, Dr Darrin Disley, commented: "This award is a testament to the strength of the Horizon team, and comes in recognition of what we have already achieved and what we are always working towards - making a difference in the lives of cancer sufferers. The award also shows how competitive a UK-based biotech company can be with its US and global counterparts. I look forward to leading Horizon in the next stages of the company's development."

To qualify for the Most Promising Company Competition, a company must be privately-held and working the areas of therapeutics, diagnostics or platform and information technologies. Selection is based on how a company's innovation is disruptive to current standard-of-care, both in cost and effectiveness; strength of team and ability to execute; barriers to competition and strength of intellectual property and expected financial returns for investors.

This year's competition started with a brief testimonial given by 2012 award winner Lissa Goldenstein, CEO of Auxoygn: "It's wonderful to be among organizations that are transforming personalized medicine and the current standard of care with disruptive technologies. As the 2012 recipient of the Most Promising Company Award, it is my honor and privilege to kick off this year's conference to celebrate organizations who are on the forefront of innovation to advance personalized medicine."

Judges for the Most Promising Company Award competition included Beth Seidenberg, M.D., Partner, Kleiner Perkins Caufield & Byers; Diego Miralles, M.D., Head, Janssen Research & Development and Janssen Healthcare Innovation; and Warren H. Hogarth, Ph.D., Partner, Sequoia Capital.

Moderated by Melinda Richter, Founder and CEO, Prescience International, the award competition included audience text vote polling which allowed PMWC 2013 attendees to help determine this year's winner.

"We are very pleased and honored to be involved in an award that features such promising scientific breakthroughs from around the world," said Richter. "This year again, the quality of the award competitors demonstrates how much personalized medicine continues to grow," continued Richter.

According to Tal Behar, co-founder of PMWC "Personalized medicine is one of the most revolutionary accomplishments mankind has ever seen. Companies highlighted during this year's competition are at the forefront of this achievement and help solve the most pressing healthcare challenges of our time."

About Personalized Medicine World Conference
Based in Silicon Valley, the Personalized Medicine World Conference (PMWC) International platform emphasizes innovation and industry, with the objective of accelerating the adoption of evidence-based medicine.
In its two-day, business, and educational conferences, PMWC brings together multidisciplinary thought-leadership the business, government, healthcare-delivery, research and technology arenas to examine how to improve the care experience to patients and address the increasing demand for high-quality, cost effective, personalized care.

About Prescience International
Prescience International (prescienceintl.com) is dedicated to accelerating the commercialization and global adoption of science and technology. With industry expertise in the future of technology markets, Prescience International creates and manages centers of excellence in the form of research parks, innovation centers, research foundations, research institutes and emerging companies. The Prescience team brings a combination of business and lab experience to translate science and technology into economic wealth and social impact. Prescience's projects have won international acclaim and the companies within these projects have demonstrated that their development times and costs are cut by at least 50 percent.

About Horizon Discovery Limited
Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. The Company's proprietary rAAV gene-editing technology, GENESIS™, is industry leading. Using GENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.
Horizon has applied GENESIS to create over 500 X-MAN™ cell lines, the world's first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These 'patients-in-a-test-tube' are being used by academic and industry leaders to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the 'right drugs' for the 'right patients' based upon the unique genetic mutations that define their disease.
In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN derived products and services, with industrial applications in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms.

GENESIS and X-MAN are registered trademarks of Horizon Discovery Limited.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Prescience International

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Personalized Medicine World Conference and Prescience International Announce Most Promising Company

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Aurelie Gaudin - PrescienceIntl.com 
415-445-4070 aurelie[.]prescienceintl.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Prescience International securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Prescience International / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)